neutral
Recently
Modern Diagnostic investors see modest gains following SME market debut
Modern Diagnostic delivers moderate listing gains, with investor focus shifting to earnings scalability and post-listing liquidity.
Investors in Modern Diagnostic and Research Centre saw limited gains after the company’s shares debuted on the BSE SME platform at a premium exceeding 10 percent. The listing outcome reflects restrained enthusiasm toward smaller IPOs despite strong subscription numbers. Market participants are now evaluating post listing liquidity, earnings scalability, and competitive positioning within regional diagnostics services.